DEPARTMENT OF HEALTH & HUMAN SERVICES

FOR US POSTAL SERVICE DELIVERY: Office of Laboratory Animal Welfare Rockledge One, Suite 360 6705 Rockledge Drive – MSC 7982 Bethesda, Maryland 20892-7982 Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

LANVICE

May 7, 2018

PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH

> FOR EXPRESS MAIL: Office of Laboratory Animal Welfare Rockledge One, Suite 360 6705 Rockledge Drive Bethesda, Maryland 20817 Telephone: (301) 496-7163 Facsimile: (301) 402-7065

Re: Animal Welfare Assurance A3381-01 [OLAW Case 2B]

Dr. Jennifer K. Lodge Vice Chancellor for Research Washington University in St. Louis 660 South Euclid Ave., Box 8108 St. Louis, MO 63130

Dear Dr. Lodge,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your April 16, 2018 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at Washington University in St. Louis, following up on an initial telephone report on April 10, 2018. According to the information provided, OLAW understands that 24 mice on a cecal ligation and puncture surgery failed to receive one of the required post-operative analgesics and several failed to receive the long acting or full dose of another analgesic. No adverse clinical signs were reported in the mice.

The corrective actions consisted of retraining the Principal Investigator and staff, ensuring that analgesics will be given as stated in the protocol, and amending the protocol to include additional analgesic regimens.

Based on its assessment of this explanation, OLAW understands that measures have been implemented to correct and prevent recurrence of this problem. OLAW concurs with the actions taken by the institution to comply with the PHS Policy.

Sincerely,

(b) (6)

Axel Wolff, M.S., D.V.M. Deputy Director Office of Laboratory Animal Welfare

cc: IACUC Chair

Washington University in St. Louis

Institutional Animal Care and Use Committee

April 16, 2018 Assurance: D16-00245 (A3381-01)

Dr. Axel Wolff, DVM, MS Deputy Director, Office of Laboratory Animal Welfare National Institutes of Health Rockledge Drive Bethesda, MD 20892-7982

Initial Report: April 10, 2018 Protocol: 20170124 "Circadian regulation of oxidative stress and neurodegeneration"

Dear Dr. Wolff,

Washington University in St. Louis (WU), in accordance with PHS Policy IV.F.3 and Assurance D16-00245, submits this final report for a non-compliant event initially reported by the IACUC Director on April 10, 2018.

During a post-approval monitoring visit and surgery records review, inspectors identified noncompliance with the approved post-operative analgesic regimen in approximately 24 mice. Mice were approved to receive Buprenorphine SR and Meloxicam following cecal ligation and puncture surgery. None of the 24 mice received meloxicam and a subset of the mice received a standard formulation of the buprenorphine. The standard buprenorphine was administered once a day (as approved in the protocol for other procedures) and not twice a day (as recommended). The animals were observed post-operatively as described in the protocol and no additional adverse clinical consequences were reported for those animals with the altered analgesic administration.

In response, the lab and PI completed retraining with members of the Quality Assurance/Quality Improvement staff and provided assurances that analgesics would be administered as described in the protocol for all future procedures. An amendment to update the analgesic options was reviewed and approved by the IACUC. The incident and completed corrective actions were reviewed by the IACUC at a convened meeting and the committee considers the incident resolved.

The protocol associated with the noncompliance was supported by NIH funding (5K08NS079405 and R01AG054517) but no specific costs were determined to be associated with the incident. In accordance with NIH Grants policy, any NIH funds directly associated with noncompliant events would be returned.

Please let me know if you have any questions or would like additional information.

Sincerely,

(b) (6)

Jénnifer K. Lodge, Ph.D. Institutional Official Vice Chancellor for Research

> Campus Box 1054, One Brookings Drive, St. Louis, MO 63130 (314)362-3229, Fax (314)747-6695, http://dx.wustl.edu

(b) (6)

Wolff, Axel (NIH/OD) [E]

From:	OLAW Division of Compliance Oversight (NIH/OD)
Sent:	Friday, May 04, 2018 7:01 AM
То:	'Moore, Meredith'
Cc:	OLAW Division of Compliance Oversight (NIH/OD)
Subject:	RE: D16-00245 (A3381-01) Final Reports

Thank you for these reports, Dr. Moore. We'll send responses soon. Axel Wolff

From: Moore, Meredith [mailto:moore577@wustl.edu] Sent: Thursday, May 03, 2018 2:51 PM To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>; Lodge, Jennifer <lodgejk@wustl.edu>; (b) (6) Moore, Meredith <moore577@wustl.edu>

Cc: accredit@aaalac.org;

(b) (6)

Subject: D16-00245 (A3381-01) Final Reports


Dr. Wolff,

Attached, please find two final reports for separate incidents at Washington University at St. Louis initially reported April 10, 2018. Our Assurance number is D16-00245 (A3381-01).

If you have any questions, please let me know.

Meredith L. Moore, PhD, CPIA Director, IACUC Office Washington University in St. Louis (b) (6)

The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail.



Projected plan and schedule for corréction/prevention (if known):

PI + lot retrained, will give drugs per protocol, aniend protecol

Projected submission to OLAW of final report from Institutional Official:

OFFICE USE ONLY Case #